Full coverage· Economy· Updated
Teva's New Schizophrenia Drug Approval Boosts Price Target to $50
Leader Capital Markets raised Teva Pharmaceutical Industries' stock price target to $50 following the FDA's approval of its new schizophrenia drug, WELTRUZA. The approval reduces regulatory risk and enhances prospects for Teva's innovative drug pipeline.
2 newsrooms · 1 language · since
Plus
What happened
- 01Leader Capital Markets raised Teva's stock price target to $50 after FDA approval of its new schizophrenia drug.
- 02The new drug, WELTRUZA, offers advantages over existing treatments, including less required medical supervision.
- 03Teva's CEO projects combined annual sales of $1.5 to $2 billion for WELTRUZA and another schizophrenia drug, UZEDY.
- 04Significant revenue from WELTRUZA is not expected until the second half of 2027 due to insurance coverage timelines.
- 05Leader's consensus estimates for Teva's third-quarter revenue are $4.25 billion.
- 06The company's performance will also be assessed based on its key drug AUSTEDO and ongoing efficiency programs.
While the drug offers significant advantages, its commercial success hinges on patient adoption and insurance coverage. Analysts project WELTRUZA's substantial revenue contribution to begin in late 2027, with limited impact on 2026 results.
The coverage
2 newsrooms on this story
Who covered it
- LeftNone
- CentreNone
- RightNone
- HarediNone
- ArabNone
- Other2
